Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Rating) in a research note issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Aptevo Therapeutics Stock Up 1.7 %

NASDAQ APVO opened at $2.44 on Tuesday. The stock has a fifty day moving average of $2.62 and a 200-day moving average of $3.21. Aptevo Therapeutics has a 52 week low of $1.94 and a 52 week high of $7.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.16 and a quick ratio of 3.16.

Aptevo Therapeutics (NASDAQ:APVO – Get Rating) last released its earnings results on Thursday, November 10th. The biotechnology company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.64) by $0.11. Analysts forecast that Aptevo Therapeutics will post -6.58 EPS for the current year.

Institutional Investors Weigh In On Aptevo Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Cantor Fitzgerald L. P. acquired a new stake in shares of Aptevo Therapeutics during the third quarter worth $406,000. Citadel Advisors LLC acquired a new stake in shares of Aptevo Therapeutics during the third quarter worth $51,000. Virtu Financial LLC grew its stake in shares of Aptevo Therapeutics by 122.6% during the third quarter. Virtu Financial LLC now owns 28,421 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 15,653 shares during the period. Renaissance Technologies LLC grew its stake in shares of Aptevo Therapeutics by 18.7% during the second quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 11,000 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Aptevo Therapeutics by 7.3% during the first quarter. Vanguard Group Inc. now owns 240,819 shares of the biotechnology company’s stock worth $1,414,000 after purchasing an additional 16,337 shares during the period. 17.04% of the stock is owned by institutional investors and hedge funds.

About Aptevo Therapeutics

(Get Rating)

Aptevo Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.